Skip to main content

Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential

In the four months since Gilead Sciences Inc. first received emergency authorization for its experimental COVID-19 drug remdesivir, its stock has done the opposite of what you would expect — it has dropped 21%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.